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Abstract
Background: Disrupting protein-protein interactions by small organic molecules is nowadays a promising strategy
employed to block protein targets involved in different pathologies. However, structural changes occurring at the
binding interfaces make difficult drug discovery processes using structure-based drug design/virtual screening
approaches. Here we focused on two homologous calcium binding proteins, calmodulin and human centrin 2,
involved in different cellular functions via protein-protein interactions, and known to undergo important
conformational changes upon ligand binding.
Results: In order to find suitable protein conformations of calmodulin and centrin for further structure-based drug
design/virtual screening, we performed in silico structural/energetic analysis and molecular docking of terphenyl
(a mimicking alpha-helical molecule known to inhibit protein-protein interactions of calmodulin) into X-ray and
NMR ensembles of calmodulin and centrin. We employed several scoring methods in order to find the best
protein conformations. Our results show that docking on NMR structures of calmodulin and centrin can be very
helpful to take into account conformational changes occurring at protein-protein interfaces.
Conclusions: NMR structures of protein-protein complexes nowadays available could efficiently be exploited for
further structure-based drug design/virtual screening processes employed to design small molecule inhibitors of
protein-protein interactions.
Background
Protein-protein interactions (PPIs) are important for
regulating many biological functions. It has been sug-
gested that the human interactome involves about
650,000 interactions [1] and disrupting these interac-
tions could be an attractive way to block a number of
targets involved in different pathologies [2,3]. A possible
strategy to inhibit undesired PPIs is to design small
organic molecules binding in the zone of interactions
and the increasing number of such recent success stor-
ies prove it [3-5]. Yet, it is difficult to efficiently target
PPIs due to large and flat interfaces [6], the nature of
the chemicals present in chemical libraries [7,8], and in
particular due to the structural changes that can occur
upon ligand binding. In some cases, small structural
changes have been observed at the PPIs interfaces due
to small inhibitors’ binding [5]. Other proteins, i.e. cal-
modulin, undergo considerable conformational changes
due to protein or small ligand binding [9]. Indeed, lim-
itations in describing potential small-molecule binding
sites have been noted when using static structures
of either the unbound protein or the protein-protein
complex [6].
Some early designed inhibitors of PPIs mimic short
secondary-structural elements of proteins [2]. Other
molecules, like the terphenyl and its derivates (mimick-
ing alpha-helical regions), were shown to be able to
inhibit several PPIs [10,11], e.g. terphenyls disrupt the
calmodulin (CaM) interactions with smooth muscle
myosin light-chain kinase (smMLCK), with 3’-5’-cyclic
nucleotide phosphodiesterase, or with the helical peptide
C20W of the plasma membrane calcium pump [12].
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Figure 1) into two homologous Ca
2+-binding proteins,
CaM and human centrin 2 (HsCen2), to find out the
CaM and HsCen2 conformations that could efficiently
be employed for further structure-based design of inhi-
bitors of PPIs. CaM and HsCen2 have a high sequence
homology (Figure 2A) and display a structural similarity
as both proteins are composed by two EF-hand N- and
C-terminal domains connected by a helical linker (see
Figure 2B). The binding of 1-naphthyl terphenyl by
CaM (IC50 = 9 nM) has already been shown experimen-
tally [12]. Following the strong similarity between the
two Ca
2+-binding proteins we probe in this study a
potential terphenyl binding into HsCen2.
CaM is expressed in all eukaryotic cells and interacts
with a large number of different protein targets [13],
being thus involved in regulation of different cellular
processes, such as cell division and differentiation, ion
transport, muscle contraction, etc. [14,15]. Ca
2+-binding
induces a rearrangement of the tertiary structure of EF-
hand domains of CaM [16] with an exposure of a large
hydrophobic cavity promoting the association of a wide
array of target proteins, including kinases, cyclases, var-
ious cell surface receptors, etc. CaM displays a multi-
tude of conformational states [17-19]. Modulation of
physiological targets of CaM through CaM inhibition by
small natural or synthetic compounds [20] may guide
discovery of new therapeutic agents.
Centrins are involved in the centrosome duplication
[21], in the nuclear excision repair (NER) mechanism
[22] or in the multiple nuclear export pathways [23].
NER is an essential molecular mechanism responsible
for repairing of DNA lesions caused by UV light or anti-
tumor agents like cis-platin. Cis-platin resistance in che-
motherapy is a major complication in cancer and seems
to be associated with the stimulation of NER DNA
repair mechanism [24]. Centrin forms a heterotrimeric
complex with XPC (Xeroderma pigmentosum group C)
and hHR23B proteins, which play a key role in the DNA
damage recognition. Recent in vivo and in vitro studies
[25,26] revealed that HsCen2 binds to a 17-mer peptide
(N847-R863) of XPC protein (P17-XPC) with a high
affinity in the presence of Ca
2+ (~ 10
8 M
-1). Human cell
lines expressing a mutant XPC protein (in the centrin
binding motif) exhibited in vitro and in vivo a significant
reduction of NER activity [25]. Thus, inhibition of cen-
trin-XPC interactions involved in the NER mechanism
might be an efficient way to modulate these processes.
Structural changes occurring at PPIs interfaces make
difficult to successfully proceed to structure-based drug
design/virtual screening of novel small molecules inhi-
biting PPIs [27-29]. Selecting appropriate conformations,
taking into account the protein plasticity, could be a
valuable starting point for subsequent structure-based
virtual screening studies. One possibility to incorporate
the protein receptor flexibility for ligand docking is to
explore multiple receptor conformations (MRC) [30,31],
either experimental [32-34] or modeled [35-39]. Once
the MRC selected, ligand candidates can be docked into
each receptor conformation and the results from each
docking run can be combined together in a post-proces-
sing step [40]. Recent papers showed examples of using
NMR ensembles of the protein receptor for docking and
screening processes [33,41]. In this work we performed
in silico analysis and docking of 1-naphthyl terphenyl
into NMR ensembles of CaM and HsCen2 that revealed
a small set of NMR conformations appropriate to
perform further structure-based virtual screening for
discovering of small PPIs inhibitors.
Results and Discussion
Protein-protein binding site analysis
CaM and HsCen2 share about 50% sequence homology
extending even to the positions of side chains in the
hydrophobic core of the proteins. The main difference
between them is the presence in HsCen2 of a 25 amino
acids N-terminal ending region (Figure 2A). Both proteins
possess four EF-hands, but for HsCen2 only the EF hands
belonging to the C-terminal domain bind Ca
2+ ions [42]
with a significant affinity (~ 10
4-10
5 M
-1). We should note
the high sequence homology of the C-terminal domains of
these two Ca
2+-binding proteins (blue and purple regions
in Figure 2A), especially in the binding sites (purple
regions in Figure 2A). The superposition of CaM and
HsCen2 structures shows their strong structural similarity
(Figure 2B). The root mean square deviations (RMSD)
between the carbon alpha atoms of the CaM and HsCen2
structures shown in Figure 2B is 3.3 Å, whereas the RMSD
between the two C-terminal domains is 0.8 Å.
The flexible helical linker between N- and C-terminal
domains enables the switch between different conforma-
tional states of CaM and HsCen2. Figures 2B and 2C
show two conformations of CaM, namely an “extended”
mode (in the absence of ligand) and a “wrap-around”
Figure 1 1-naphthyl therphenyl structure colored by atom
type. The pharmacophoric points chosen for docking accuracy
evaluation are shown as purple circles for CaM: 1, 1’, and 2, and for
HsCen2: 1, 2, and 3.
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In the last one, the central helix becomes partially
unstructured and the helices of the N-terminal domain
point toward the bound trifluorperasine molecules. It has
been demonstrated that the C-terminal domain of CaM
(C-CaM) binds several peptides/proteins [43]. Similarly,
the terphenyl molecule (mimicking the CaM-binding face
of smMLCK), binds exclusively into the C-domain of
C a M[ 1 2 ] .T h er e s i d u e sW 4 ,T 7a n dV 1 1o fs m M L C K
(noted as i, i + 3, i + 7 of the alpha-helix) are critical for
the interaction with C-CaM [16].
Similarly, HsCen2 undergoes important conformational
changes depending on the presence of a bound ligand
(see Figure 2B and 2D) [18]. In the HsCen2/P17-XPC
Figure 2 Sequence and structural homology of calmodulin and centrin. (A) sequence alignment of CaM and HsCen2, the C-terminal
domains are shown in blue and the pocket regions in magenta; (B) superposition of the X-ray structures of CaM (yellow cartoon, unbound form,
code 1CLL) and HsCen2 (blue cartoon, bound form, code 2GGM); (C) CaM in a complex with trifluorperasine (sticks in magenta) (code 1LIN); (D)
structure of HsCen2 (unbound form, code 1M39). The blue region corresponds to the C-domain of HsCen2; the helix (in cyan) belongs to the N-
terminal domain.
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domains undertakes an extended form (Figure 2B), and
in the unliganded form the same region closes the
C-terminal peptide binding site (Figure 2D). Structural
studies showed that HsCen2 binds the 17-mer XPC pep-
tide only by its C-terminal domain and the W2, L5 and
L9 residues (1-4-8 motif) of the P17-XPC have been
shown as critical anchoring side chains [26,44]. Thermo-
dynamic studies [26] enabled the definition of a minimal
centrin binding site, a peptide of five residues, which
accounted for about 75% of the total free energy of inter-
action between the two proteins.
The above presented data indicate that the C-terminal
domains of both Ca
2+-binding proteins are more func-
tional regarding the peptides binding. Therefore, we
explored the C-terminal domains of CaM and HsCen2
for potential small ligands’ binding. We analyzed several
X-ray structures and NMR ensembles of both proteins
to construct a relevant ensemble of multiple receptor
conformations for the docking process of 1-naphthyl
terphenyl. The selected sets contained crystal structures
as well as 31 NMR structures (among 160 ones) and 20
NMR structures for C-CaM and C-HsCen2, respectively
(see for details the Methods section). The selected NMR
and X-ray structures of C-CaM and C-HsCen2 are
shown in Figure 3. The residue numbers correspond to
the ones in the NMR files, 2K0F for CaM and 2A4J for
HsCen2.
Docking of terphenyl
The docking-scoring protocol employed to dock
1-naphthyl terphenyl into the selected structures is
shown in Figure 4 (see for details in the Methods sec-
tion). In order to identify the “best” protein conforma-
tions for further analysis, we calculated the RMSD
between each pose obtained after docking with
DOCK6.0 [45] and the reference points of smMLCK
and P17-XPC for CaM and HsCen2, respectively (see
Figure 1). The obtained RMSD values are shown in
Figure 5A and 5B. Overall, docking results are best for
the structures of C-HsCen2. We compared the binding
zones of the two proteins to analyze these results. For
C-CaM, the binding pocket consists of one cavity
(volume 314.22 Å
3, code 1CLL) containing residues F88,
I96, L101, M105, M120, E123, M140 and M141. The
residue F88 placed in the center of the binding zone is
in contact with W4 and T7 of the smMLCK peptide.
The binding site of HsCen2 is larger (volume 417.27 Å
3,
code 2GGM) and consists of two hydrophobic cavities
separated by F113 interacting with L5 of the P17-XPC
peptide, and L126 and M145 interacting with W2 of the
peptide. The close contact of F113 and L5 of the bound
peptide has also been observed in the structure of HsCen2
complexed with another protein partner targeting the
same HsCen2 zone [46]. The deeper and bigger cavity
contains the residues F113, I146, E148, V157, I165 and
M166, and the smaller one contains the residues L126,
V129, A130, L137, L142 and M145. The replacement of
one Met residue (M105) of C-CaM with a smaller one, an
Ala residue (A130), enlarges the hydrophobic cavity of the
C-HsCen2. This facilitates a potential anchoring of
1-naphthyl terphenyl into the C-HsCen2.
We also compared the flexibility of the binding zone
of CaM and HsCen2, by analyzing the B-factors of the
carbon alpha atoms for all residues in the binding
pocket of HsCen2 complexed with P17-XPC, as well as
for a few complexes of human CaM interacting with
helical peptides of similar length as P17-XPC (PDB
codes: 3EWV, 1IWQ, 2VAY, 1ZUZ, 3BYA, and 1YR5).
This analysis showed an enhanced flexibility of CaM in
a bound state, in the region 107-113 compared to the
binding zone 132-138 of HsCen2. Structural comparison
of these complexes suggested that this difference would
be mainly due to a higher mobility of the K111 side
chain of CaM compared to N136 of HsCen2. Moreover,
we should note the presence of four Met residues in the
binding site of C-CaM (M105, M120, M140, M141) and
two Met residues in the pocket of C-HsCen2 (M145
and M166). The flexible nature of the Met side chains
at the binding surface has previously been discussed as a
critical factor to facilitate the surface complementarity
between CaM and its partner [19,47]. This analysis
shows a higher plasticity of the binding pocket of the
C-CaM than the C-HsCen2, and, therefore, more struc-
tural arrangements might occur for the C-CaM than for
the C-HsCen2 upon ligand binding.
The 3D electrostatic potential distribution on the
X-ray C-CaM and C-HsCen2 surfaces (see Figure 6)
indicates that overall C-CaM is more negatively charged
than C-HsCen2; this could be related with the stronger
affinity of Ca
2+ for CaM than HsCen2 [48]. This obser-
vation is also valid for the binding zone of the C-CaM
and C-HsCen2. The presence of a large number of
negatively charged residues in both proteins, and espe-
cially in C-CaM, resulted in several computed abnormal
pKa values for C-CaM: 7.3 for E100, 8.4 for D129, and
7.6 for E136; for HsCen2: 6.6 for D114 and 7.4 for D154
(these residues are not situated in the binding pocket).
The mean local hydrophobic density calculated using
Fpocket tool [49] was 41.39 and 54.78 for the binding
pockets of C-CaM and C-HsCen2, respectively. Follow-
ing these results, we can speculate that the higher
hydrophobicity of C-HsCen2 binding zone might facili-
tate a potential binding of the hydrophobic 1-naphthyl
terphenyl.
The RMSD results allowed to retain for further analysis
five best NMR models for the C-HsCen2 and C-CaM, in
addition to the X-ray structures (for CaM:2K0F: models
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Page 4 of 1231, 76, 98, 156 and 160; for HsCen2:2A4J models 1, 5, 6,
7 and 17). As can be seen for both proteins better dock-
ing poses were obtained when docking on some of the
NMR conformations compared to the X-ray ones. The
binding pockets of the five best NMR models have larger
volumes than the X-ray structures for both proteins. For
C-CaM, the cavity is deeper in the selected NMR models
(e.g. the volume is 399 Å
3 for the model 31) than in the
X-ray structure (volume 314 Å
3). The binding pocket of
the X-ray structure ofH s C e n 2( v o l u m e4 1 7Å
3)i sm u c h
smaller than those of the best five NMR models
(volumes: 1043 Å
3 for model 1, 934 Å
3 for model 5, 1419
Å
3 for models 6, 1277 Å
3 for models 7 and 1134 Å
3 for
model 17), that obviously makes easier the terphenyl
docking into these NMR structures. We suggest that this
observation would be valid as well for other small ligands’
docking. The large difference between the pocket
volumes of the best NMR models and X-ray structure of
C-HsCen2 is due to the orientation of two residues, F113
and F162, that fill a large part of the binding cavity in
the X-ray structure. Similar situation was observed for
C-CaM and F88.
Poses’ refinement and interaction energy analysis
As previously shown [50,51], post-docking optimization
may help to further improve both docking poses and
scores. We performed additional energetic analysis (see
Tables 1 and 2) of docking poses on the selected best
Figure 3 Superposition of the C-terminal domains of CaM and HsCen2 used for docking. (A) 31 NMR (code 2K0F; in grey cartoon) and
one X-ray (code 1CLL; in green cartoon) structures of CaM. One of the NMR smMLCK peptide structures bound to CaM is shown in pink (code
2K0F); (B) 20 NMR (code 2A4J; in grey cartoon) and one X-ray (code 2GGM; in green cartoon) structures of HsCen2. The peptide P17-XPC bound
to HsCen2 is shown in pink (code 2GGM); (C) surface presentation of the X-ray structure of CaM (code 1CLL); (D) surface presentation of the
X-ray structure of HsCen2 (code 2GGM). The sticks in pink represent the positions of the peptide residues i, i + 3, i + 7 key for the binding.
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re-calculate the interaction energies taking into account
desolvation effects due to ligand binding. Firstly, we car-
ried out an energy minimization of the docking poses
on the selected NMR conformations and X-ray struc-
tures of both proteins using the program AMMOS [52].
The included flexible side chains of the protein receptor
around the bound terphenyl enabled to relax the com-
plex structures in the binding pocket. The energy gain
due to the AMMOS relaxation for the best scored poses
is shown in Tables 1 and 2. The important energy
decrease during this step is due to reducing clashes
between the docked ligand and some residues of the
protein binding pocket, as well as internal ligand energy
optimization. Figure 7 represents the side-chain orienta-
t i o n sa f t e rt h ee n e r g ym i n i m i z a t i o nf o rt h ed i f f e r e n t
docking poses. The residues slightly moving due to the
optimization are F88, L101, M105, E110, M120, E123,
and M140 for CaM (Figure 7A) and F113, L126, E132,
M145, E148 and E161 for HsCen2 (Figure 7B). Interest-
ingly, it can be seen that Met residues M105, M120 and
M140 are among the moving residues, as discussed
above. As seen in Figure 7, the changes due to the opti-
mization are not very large, still small variations of the
docked complex structure can affect the interaction
energy prediction (see Tables 1 and 2, the AMMOS
energy, before and after AMMOS refinement). It has
been previously discussed that even small receptor
movements can lead to important modifications into the
molecular recognition pattern and/or binding energy
prediction errors [53]. To this end, the AMMOS refine-
ment step could be useful to “rescue” some docking
poses with bad energy score after docking on a rigid
receptor (e.g. the docking pose 19 on the 2K0F model
160, Table 1).
Further, we employed re-scoring with the GBSA
Hawking model as implemented in DOCK6.0, and re-
scoring with X-Score [54] on the AMMOS optimized
docked complex structures. Tables 1 and 2 show the
top scored poses retrieved by each of the methods:
Figure 4 Flowchart of the employed docking-scoring protocol.
Figure 5 Box plots of RMDS values (Å) between the docking
poses of terphenyl and the reference pharmacophoric points.
The box region corresponds to the 50% of the distribution, with
shown median. (A) docking into the X-ray (code 1CLL) and the 31
NMR structures (code 2K0F) of CaM; (B) docking on the X-ray
(code 2GGM) and the 20 NMR structures (code 2A4J ) of HsCen2.
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Page 6 of 12Figure 6 Electrostatic potential distribution on the protein surface of the C-terminal domains. (A) CaM; (B) HsCen2. The potential
computed using PCE [59] is shown from -3.0 kcal/mol/e (red) to +3.0 kcal/mol/e (blue). The residue numbers correspond to the ones in the
NMR files, 2K0F for CaM and 2A4J for HsCen2.
Table 1 Terphenyl-CaM interaction energy (in kcal/mol) predicted by the methods DOCK, AMMOS, GBSA, X-Score for
the top scored poses
RMSD (Å) DOCK vdw + es AMMOS vdw + es GBSA vdw + es X-Score
Receptor structure No pose before AMMOS refinement after AMMOS refinement
1CLL
1 3.3 -48.63 -14.90 -26.09 -52.53 5.95
2 4.8 -48.27 -9.71 -26.72 -61.12 6.31
3 3.0 -48.15 -18.32 -29.91 -56.85 6.38
2K0F model 31
1 1.9 -42.70 -13.04 -36.42 -40.05 6.78
2 8.8 -41.70 -12.64 -26.45 -46.17 6.68
2K0F model 76
1 4.5 -48.12 -4.24 -22.43 -31.43 6.24
5 3.3 -45.71 -20.72 -34.51 -46.11 6.86
8 3.1 -44.68 -20.23 -30.63 -49.13 6.81
2K0F model 98
1 8.8 -49.79 3.37 -16.05 -21.64 6.14
16 7.9 -38.89 5.71 -17.65 -23.62 5.77
17 7.4 -38.32 48.93 -4.83 -31.53 6.34
2K0F model 156
1 8.2 -50.52 -6.90 -13.17 -34.42 4.31
6 2.3 -45.57 -13.08 -36.31 -48.90 4.69
12 2.5 -43.51 -19.25 -34.35 -49.93 4.89
2K0F model 160
1 8.7 -41.13 3.15 -4.23 -40.65 4.81
2 5.3 -40.57 1.36 -6.20 -49.48 4.64
19 2.3 -19.66 43.66 -41.25 -38.44 5.03
The column 2 shows the RMSD of the poses as predicted by DOCK.
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docking poses of bound terphenyl within 2.5 Å RMSD as
acceptable. The best protein conformations for CaM and
HsCen2 were found by consensus between AMMOS,
GBSA and X-Score re-scoring if the best score corresponds
to a good RMSD pose. Among the twelve protein struc-
tures, 1CLL, 2K0F model 76, and 2K0F model 98 were
considered as “bad” because no one of the re-scoring meth-
ods AMMOS, GBSA and X-score retrieved good docking
poses. The AMMOS energy and X-Score retrieved good
docking poses for 8 out of the 9 remaining acceptable
cases. GBSA scoring found good poses for 6 out of the 9
acceptable cases. Figure 8 illustrates one good and one bad
solutions found by GBSA. In the case of NMR model 5 of
C-HsCen2, (Figure 8B), GBSA retrieved a good docking
pose. However, for the NMR model 31 of C-CaM, (Figure
8A), the pose retrieved by GBSA is completely upside-
d o w n .G B S Af a i l e dt of i n dt h eg o o dp o s e si n3o u to f9
possible cases. Similar problems (taking into account more
complex physical terms, via PBSA or GBSA methods, that
demand precise positions of the protein and ligand atoms)
have already been found in other docking studies [51,55].
I tm i g h tb ep o s s i b l et h a taf u r t h e ro p t i m i z a t i o no ft h e
docked complexes including an implicit solvent or explicit
water molecules during the minimization would be useful
for a more successful re-scoring with the GBSA method.
The results in Table 1 reveal the best C-CaM confor-
mations suitable for further structure-based drug
design/virtual screening: the best one is 2K0F model
156 where the good docking poses were found by the
three re-scoring scoring methods; the models 2K0F 31
and 160 are acceptable with good poses found by
AMMOS and X-Score. In the case of HsCen2 (Table 2),
the 2A4J models 5, 6, 7, and 17 appear to be best ones
where the three re-scoring methods retrieved the good
docking poses; the 2A4J model 1 is acceptable with
good poses found again by AMMOS and X-Score.
Conclusions
This work highlights that scoring and docking accuracy
strongly depend on considering the receptor flexibility,
either large conformational changes or small side-chain
adjustments in the protein-protein binding region occur.
Exploiting the NMR ensembles could be very helpful to
take into account the receptor conformational changes
into docking/virtual screening exercises. Local induced-
fit optimization in a protein-ligand complex structure
can be achieved by using the AMMOS method. We
explored docking of terphenyl on a number of NMR
conformations vs X-ray structures of CaM and HsCen2.
Using the NMR ensembles of the receptor structure sub-
stantially improved the docking and scoring compared to
Table 2 Terphenyl-HsCen2 interaction energy (in kcal/mol) predicted by the methods DOCK, AMMOS, GBSA, X-Score
for the top scored poses
RMSD (Å) DOCK vdw + es AMMOS energy vdw + es GBSA vdw + es X-Score
Receptor structure No pose before AMMOS refinement after AMMOS refinement
2GGM
1 2.7 -56.10 >2000 -38.74 -72.47 7.01
13 2.2 -49.02 >2000 -19.93 -74.13 6.56
2A4J model 1
1 1.3 -69.63 -33.45 -56.14 -66.68 8.19
2 1.4 -67.60 -30.10 -50.40 -67.88 8.21
7 9.7 -63.23 -34.75 -39.31 -76.58 7.66
2A4J model 5
1 1.8 -65.07 -20.30 -46.75 -67.91 7.80
4 1.6 -63.82 -18.92 -48.72 -59.92 8.26
2A4J model 6
1 1.7 -64.29 29.11 -49.35 -69.97 7.99
3 1.9 -62.29 -15.63 -39.59 -67.46 8.00
9 1.8 -60.66 37.90 -47.70 -70.74 7.98
2A4J model 7
1 1.6 -65.88 -23.25 -41.74 -73.64 8.16
2 1.6 -65.09 -19.22 -38.49 -75.20 8.31
2A4J model 17
1 1.5 -66.54 145.48 -28.03 -79.76 8.08
7 1.7 -63.64 635.45 -41.46 -76.38 7.79
10 1.4 -63.18 >2000 -35.88 -77.15 8.21
The column 2 shows the RMSD of the poses as predicted by DOCK.
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conformations of CaM and HsCen2 suitable for small
ligand docking/virtual screening targeting the CaM and
HsCen2 interactions. The comparative structural and
energetic analysis of the binding sites of both proteins
demonstrate large similarities and some differences. All
together these data can be valuable for a future design of
small PPIs inhibitors for CaM and HsCen2.
Methods
Selection of CaM and HsCen2 structures and binding
pocket analysis
X-ray structures and NMR ensembles of CaM and
HsCen2, all in the Ca
2+-bound state, have been taken
from the Protein Data Bank [56] and analyzed in details
as follows: i) For CaM: an unliganded X-ray structure,
code 1CLL at 1.7 Å resolution [57]; a NMR ensemble of
160 unliganded structures, code 2K0E [58]; a NMR
ensemble of 160 structures bound to 19-mer peptide
from smMLCK, code 2K0F [58]; ii) For HsCen2: a NMR
ensemble of unliganded C-terminal domain, code 1M39;
a X-ray structure of HsCen2 bound to the P17-XPC
peptide, code 2GGM at 2.35 Å resolution [44]; a NMR
ensemble of 20 structures of HsCen2 bound to P17-
XPC, code 2A4J [48].
For CaM, the X-ray structure of the human unli-
ganded CaM (1CLL) with the highest resolution among
other retrieved X-ray CaM structures (PDB codes: 1LIN,
3EWV, 1IWQ, 2VAY, 1ZUZ, 3BYA, 1YR5) has been
considered for docking calculations. We selected the
NMR ensemble 2K0F for docking experiments as the
Figure 7 Side chains of the protein residues moving after the
refinement with AMMOS (in pink sticks). The top AMMOS scored
poses of terphenyl are shown in yellow sticks. (A) CaM, the 2K0F
model 31; (B) HsCen2, the 2A4J model 5.
Figure 8 Superposition of the top scored poses of terphenyl.
The poses after docking-scoring with DOCK6.0 are shown in cyan
and the poses after the GBSA re-scoring are shown in orange. (A)
CaM, the 2K0F model 31; (B) HsCen2, the 2A4J model 5.
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V11) (see Figure 3) [16] of the bound helical peptide
smMLCK can be mimicked by the docked 1-naphthyl
terphenyl.
For HsCen2, we have taken the X-ray structure of
HsCen2 extracted from the complex with the P17-XPC
peptide (code PDB 2GGM). In the NMR ensemble
1M39, the helix F86-Q95 enters in the binding site and
closes the conformation. For 2A4J, the C-terminal
domain of HsCen2 is in an open conformation and the
binding site is occupied by the side chains of the bulky
hydrophobic residues W2, L5 and L9 of P17-XPC. Tak-
ing into account that 1-naphthyl terphenyl mimics the
binding motif i, i + 3, i + 7 (residues W2, L5 and L9) of
P17-XPC, we have considered the 2A4J ensemble for
our docking experiments.
The superposition and the analysis of all mentioned
structures when focusing on the protein binding sites of
CaM and HsCen2, revealed that the pockets are quite
similar in the NMR ensembles 2K0F and 2A4J. The bound
peptides open the protein binding sites, which enables tar-
geting by other binders. In the case of 2K0F, including 160
models, we have chosen those 31 models giving the better
superposition of the binding zone into the X-ray structure
1CLL. The residues 4-12 of 19-mer smMLCK peptide
bound in 2K0F was considered to define the binding
pocket. The residues 2-10 of P17-XPC peptide were used
to define the binding site of C-HsCen2. Thus, for all
selected protein structures of C-CaM and C-HsCen2, the
pocket region involved the residues 88-142 and 112-166,
respectively.
Using the on-line tool Fpocket [49] we calculated the
volume and the local hydrophobic density of the binding
pockets. The on-line tool PCE “Protein Continuum
Electrostatics” [59] was used to calculate the pKa values
o ft h et i t r a t a b l eg r o u p sa sw e l la st h e3 De l e c t r o s t a t i c
potential distribution of the C-terminal domains on the
X-ray CaM (code 1CLL) and HsCen2 (code 2GGM)
structures including the Ca
2+ atoms and taking dielectric
constants of the solute and solvent as 11 and 80,
respectively.
Molecular docking
Figure 4 represents the entire workflow of the docking-
scoring procedure. For all selected protein structures,
the binding sites were prepared uniformly as input for
docking experiments using the Dock Prep tool of Chi-
mera [60]. Water molecules were removed from the
protein binding sites and hydrogen atoms were added.
The molecular surface of the receptor structures was
computed using the program DMS [61] with a probe
radius of 1.4 Å. For docking of 1-naphthyl terphenyl we
used the program DOCK6.0 [45] accomplishing a
sphere-matching algorithm via an “anchor-first”
algorithm to fit ligand atoms to spheres representing a
negative image of the receptor binding site. For ligand
rotatable bonds we applied our optimized parameters
[62] to better handle the ligand flexibility. The spheres
were generated using the program SPHGEN [63]. We
selected the set of spheres representing the binding site
within 4 Å around the reference ligand, the bound
peptides smMLCK and P17-XPC for C-CaM and
C-HsCen2, respectively. The 3D structure of 1-naphthyl
terphenyl was generated using the in-house program
DG-AMMOS [64]. During the docking run, a maximum
of 1000 orientations have been generated for each
anchor and the DOCK grid energy score including elec-
trostatic and van der Waals interactions was employed.
The top 20 scored poses were retained for further consid-
eration. In order to validate the docking performance of
DOCK6.0 we performed self-docking test with trifluopera-
zine on the X-ray PDB structure of the CaM-trifluoperazine
complex (code 1CTR, 1:1 complex) following the same pro-
tocol. Three of the top 20 scored poses showed RMSD with
the bioactive trifluoperazine conformation of 1.5 - 2 Å
which can be considered as good results keeping in mind
the large binding pocket of CaM.
To evaluate the docking of 1-naphthyl terphenyl into
CaM and HsCen2 we calculated the RMSD values
between the docking poses and the bound peptides for
each retained pose. The RMSD values were computed on
the pharmacophoric points of 1-naphthyl terphenyl (see
Figure 1) as follows: for CaM: the middle point between
the atoms CD2 and CE2 of W4 (i residue) corresponding
to the point 1, the CA atom of W4 corresponding to the
point 1’,a n dt h ea t o mC Ao fT 7( i+3residue) corre-
sponding to the point 2; for HsCen2: the middle point
between the atoms CD2 and CE2 of W2 corresponding to
the point 1 (i residue), the atom CA of L5 (i+3residue)
corresponding to the point 2, and the atom CA of L9 (i+
7 residue) corresponding to the point 3.
Post-docking refinement and re-scoring
We used the open source program AMMOS recently
developed by our group [52] for pose refinement on the
best NMR and X-ray protein structures. We employed
an energy minimization to refine all poses retained after
DOCK6.0 docking on the selected protein receptor con-
formations allowing flexible ligand and flexible side
chains of the receptor residues inside of a sphere with
radius 6 Å around the ligand.
Next, we performed re-scoring on the AMMOS mini-
mized docking poses with the Generalized Born/solvent
accessible surface area (GBSA) method estimating the
electrostatic/nonpolar contribution to solvation by
employing the Hawkins GBSA method available in
DOCK6.0. The Hawkins GBSA score is an implementa-
tion of the Molecular Mechanics Generalized Born
Isvoran et al. BMC Structural Biology 2011, 11:24
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Page 10 of 12Surface Area (MM-GBSA) method originally described
by [65]. The Ca
2+ ions were included in the GBSA com-
putations and the charges of titratable protein groups
were assigned corresponding to the performed pKa cal-
culations. The nonbonded van der Waals and electro-
s t a t i ci n t e r a c t i o nt e r m sw e r et a k e ni nt h ef i n a lG B S A
scoring.
In addition, we performed re-scoring on the AMMOS
minimized docking poses by using the program X-Score
[54] developed for binding affinity estimation [66]. The
X-Score empirical scoring functions implemented in X-
Score, HSScore, HPScore and HMScore, include terms
for: van der Waals interactions, hydrogen bonds, hydro-
phobic effects, a torsional entropy penalty and a regres-
sion constant. They differ in the manner of estimation
of the hydrophobic effects. We used the averaged score
of the three X-Score functions.
All structure figures were generated with PYMOL
software [67].
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